All News

2018

December

Media Release / Dec 06, 2018

Update on Launch Plans for SYMJEPI™ (epinephrine) in the US

Read More
Media Release / Dec 06, 2018

Sandoz biosimilar Zarxio™ (filgrastim-sndz) reduced out-of-pocket costs for Medicare patients with breast cancer versus the reference medicine

Read More

November

Media Release / Nov 19, 2018

Sandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use Disorder

Read More
Media Release / Nov 08, 2018

Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)

Read More
Media Release / Nov 02, 2018

Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs

Read More

October

Media Release / Oct 31, 2018

Sandoz receives US FDA approval for biosimilar Hyrimoz™ (adalimumab-adaz)

Read More
Media Release / Oct 23, 2018

Sandoz delivers positive results for proposed biosimilars adalimumab and etanercept

Read More
Media Release / Oct 08, 2018

Sandoz Healthcare Access Challenge (HACk) launches in US, seeking digital solutions to local healthcare access challenges

Read More

September

Media Release / Sep 27, 2018

Sandoz Inc. announces US FDA approval of pediatric dose of SYMJEPI™ (epinephrine)

Read More
Media Release / Sep 06, 2018

Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo

Read More